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Abstract
L-DOPA is therapeutically efficacious in patients with Parkinson’s disease (PD), although dopamine (DA) neurons are
severely degenerated. Since cortical astrocytes express neutral amino acid transporter (LAT) and DA transporter (DAT), the
uptake and metabolism of L-DOPA and DA in striatal astrocytes may influence their availability in the dopaminergic system
of PD. To assess possible L-DOPA- and DA-uptake and metabolic properties of striatal astrocytes, we examined the
expression of L-DOPA, DA and DAT in striatal astrocytes of hemi-parkinsonian model rats after repeated L-DOPA
administration, and measured the contents of L-DOPA, DA and their metabolite in primary cultured striatal astrocytes after
L-DOPA/DA treatment. Repeated injections of L-DOPA induced apparent L-DOPA- and DA-immunoreactivities and marked
expression of DAT in reactive astrocytes on the lesioned side of the striatum in hemi-parkinsonian rats. Exposure to DA for
4 h significantly increased the levels of DA and its metabolite DOPAC in cultured striatal astrocytes. L-DOPA was also
markedly increased in cultured striatal astrocytes after 4-h L-DOPA exposure, but DA was not detected 4 or 8 h after L-DOPA
treatment, despite the expression of aromatic amino acid decarboxylase in astrocytes. Furthermore, the intracellular level of
L-DOPA in cultured striatal astrocytes decreased rapidly after removal of extracellular L-DOPA. The results suggest that DA
uptaken into striatal astrocytes is rapidly metabolized and that striatal astrocytes act as a reservoir of L-DOPA that govern
the uptake or release of L-DOPA depending on extracellular L-DOPA concentration, but are less capable of converting L-
DOPA to DA.
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Introduction
L-DOPA therapy is used in Parkinson’s disease (PD) to
replenish with dopamine (DA) in damaged dopaminergic neural
system. Although DA neurons are severely degenerated, L-DOPA
is therapeutically efficacious in patients with PD and animal
models of this disease. Where and how is DA synthesized in
patients treated with L-DOPA? It is thought that L-DOPA is
uptaken by serotonergic neurons or surviving sprouted dopami-
nergic neurons [1,2,3,4] to synthesize DA, because serotonin
neurons possess a common monoamine-synthesizing enzyme;
aromatic amino acid decarboxylase (AADC). Previous reports
demonstrated that repeated administrations of L-DOPA markedly
increased DA turnover on the lesioned side of the striatum in
hemi-parkinsonian rats [5,6].
On the other hand, the expression of membrane receptors,
channels and transporters in astrocytes is thought to be involved in
neuron-astrocyte communication [7,8,9,10]. Especially, neutral
amino acid transporter (LAT) and DA transporter (DAT) are
expressed in cortical and hippocampal astrocytes [11,12,13,14,15].
Based on the above background, we postulated that the uptake
and metabolism of L-DOPA and DA in striatal astrocytes
influences their availability in the dopaminergic system of PD
patients. To assess L-DOPA- or DA-uptake property of striatal
astrocytes in damaged dopaminergic neuronal system, we exam-
ined the expression of L-DOPA, DA and DAT in striatal
astrocytes in a hemi-parkinsonian animal model injected repeat-
edly with L-DOPA and in cultured striatal astrocytes. To clarify
the uptake, metabolism and release of L-DOPA and DA in striatal
astrocytes, the contents of L-DOPA, DA and their metabolite in




All animal procedures described in our experiments were in
strict accordance with the Guideline for Animal Experiments of
Okayama University Advanced Science Research Center, and
were approved by the Animal Care Use Committee of Okayama
University Advanced Science Research Center. Special care was
taken to minimize the number of animals used in this research.
Male Sprague-Dawley rats and timed pregnant Sprague-Dawley
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rats were purchased from Charles River Japan, Inc. (Yokohama,
Japan).
L-DOPA treatment of hemi-parkinsonian rats
Unilateral nigrostriatal dopaminergic lesions were generated
using 6-hydroxydopamine (6-OHDA) and the method described
previously with some modification [6]. Briefly, 6-OHDA hydro-
bromide (Sigma-Aldrich Corp., St. Louis, MO; 4 mg in 2 ml saline
containing 0.1% ascorbate) was injected at two sites (4 mg/site) in
the right medial forebrain bundle of 9-week-old male Sprague-
Dawley rats under pentobarbital anesthesia (50 mg/kg, i.p.) at the
following coordinates: A 21.0 mm, L +1.8 mm, V +8.5 mm; A 2
Figure 1. Schematic illustration of the protocols used for treatment of cultured striatal astrocytes for measurements of L-DOPA, DA
and its metabolite after exposure to methyl-L-DOPA or DA (left, corresponding to Table 1), for measurements of L-DOPA after
withdrawal of L-DOPA (middle, corresponding to Fig. 7), and for measurements of L-DOPA, DA and DOPAC in striatal astrocytes
cocultured with mesencephalic neurons after methyl-L-DOPA exposure (right, corresponding to Table 2).
doi:10.1371/journal.pone.0106362.g001
Figure 2. Expression of L-DOPA in reactive astrocytes in the lesioned side of the striatum of hemi-parkinsonian rats after L-DOPA
administration. Confocal laser-scanning microscopic images of double immunofluorescein staining of L-DOPA (Alexa Fluor 488; green) and GFAP
(Alexa Fluor 594; red) in the striatum of 6-OHDA-lesioned hemi-parkinsonian rats, and effects of repeated L-DOPA/carbidopa treatment (50/5 mg/kg/
day, i.p.) for 7 days. Lower panels show immunoreactivity to L-DOPA. L-DOPA-immunopositive signals (white arrows) were observed in GFAP-labeled
striatal astrocytes, especially on the lesioned side of PD models. Right small panels show higher magnification images of immunopositive signals in
the L-DOPA-treated PD models. Scale bar = 50 mm.
doi:10.1371/journal.pone.0106362.g002
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1.4 mm, L +1.5 mm, V +8.0 mm from the bregma, according to
the atlas of the rat brain [16] (upper incisor bar set 5.0 mm above
the interaural line). Sham-operated control rats were injected with
the same volume of saline containing 0.1% ascorbate. Apomor-
phine-induced rotation test was performed 2 weeks after 6-OHDA
injection to confirm induction of the lesion by 6-OHDA.
Approximately 60% of 6-OHDA-lesioned rats showed rotation
behavior after apomorphine injection (0.1 mg/kg, s.c.). Rats that
exhibited asymmetric rotation behavior towards the contralateral
side of .50 turns/10 min after apomorphine injection were
selected as hemi-parkinsonian models for the subsequent study.
Three weeks after 6-OHDA lesioning (at 1 week after
apomorphine test), the hemi-parkinsonian rats were injected
intraperitoneally with L-DOPA (50 mg/kg/day)/carbidopa
Figure 3. Changes in L-DOPA-immunoreactivity on reactive astrocytes in the striatum of hemi-parkinsonian rats after L-DOPA
administration. The 6-OHDA-lesioned hemi-parkinsonian rats were treated with L-DOPA/carbidopa treatment (50/5 mg/kg/day, i.p.) for 7 days. The
densities of GFAP-positive reactive astrocytes (A), and L-DOPA- and GFAP-double positive astrocytes (B) on both the control and lesioned sides of the
striatum were evaluated by double immunostaining of L-DOPA and GFAP at 3 h after the final administration. Values are mean 6 SEM of 8–10 mice.
*p,0.05, ***p,0.001 vs. side-matched vehicle-treated sham-operated, +++p,0.001 vs. side-matched vehicle-treated parkinsonian group, ###p,
0.001 vs. intact control side of each treated group.
doi:10.1371/journal.pone.0106362.g003
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(5 mg/kg/day) or the same volume of vehicle 0.25% methylcel-
lulose once a day for 7 days. At 3 h after the final administration,
the rats were deeply anesthetized and transcardially perfused with
ice-cold saline followed by a fixative containing 4% paraformal-
dehyde (PFA), 0.35% glutaraldehyde in 0.1 M phosphate buffer
(PB; pH 7.4). The brains were immediately removed from the skull
and post-fixed for 24 h in a fixative containing 4% PFA in 0.1 M
PB. After cryoprotection for 72 h in 15% sucrose in 0.1 M PB with
0.1% sodium azide, the brains were frozen and cut into 20-mm
coronal sections on a cryostat. Finally, the brain sections
containing the mid-striatum (+2.20 to +0.26 mm from the bregma)
were stored in 10 mM phosphate-buffered saline (PBS) with 0.1%
sodium azide at 4uC until staining.
Fluorescence immunohistochemistry of rat brain sections
The rat brain sections were incubated in 1% normal goat serum
for 30 min at room temperature (RT), and then reacted with
mouse anti-glial fibrillary acidic protein (GFAP) monoclonal
antibody (dilution; 1:10,000; Millipore, Temecula, CA,
#MAB360) and either rabbit anti-L-DOPA polyclonal antibody
(dilution; 1:250; Abnova, PAB0031), rabbit anti-DA polyclonal
antibody (dilution; 1:200; Millipore, #AB122S) or rabbit anti-
DAT polyclonal antibody (dilution; 1:1,000; Millipore,
#AB1591P) for 18 h at 4uC. The antibodies were diluted in
10 mM PBS containing 0.2% Triton X-100 (0.2% PBST). After
washing in 0.2% PBST (565 min), the sections were reacted for
2 h at RT with fluorescence-conjugated secondary antibodies. The
secondary antibodies used were goat anti-mouse IgG Alexa Fluor
594- or anti-rabbit IgG Alexa Fluor 488-conjugated antibody
(dilution; 1:1000; Molecular Probes, Eugene, OR) for GFAP/L-
DOPA staining and goat anti-mouse IgG fluorescent isothiocya-
nate (FITC)-conjugated antibody (dilution; 1:500; Millipore) and
goat anti-rabbit IgG rhodamine-conjugated antibody (dilution;
1:250; Millipore) for GFAP/DA or DAT staining.
Cell culture
Primary striatal or mesencephalic cell cultures were prepared as
descried previously [17] with minor modifications [18]. Briefly, the
striatum and mesencephalon were dissected out from Sprague-
Dawley rat embryos at 15 days of gestation. After treatment with
trypsin, cells from the striatum or mesencephalon were incubated
with 0.004% deoxyribonuclease I and 0.03% trypsin inhibitor
(Sigma-Aldrich) at 37uC for 7 min. After centrifugation
(420 g65 min), the cell pellet was gently resuspended in 4 ml of
Dulbecco’s Modified Eagle Medium (DMEM; Gibco BRL,
Rockville, MD) supplemented with 10% fetal bovine serum,
4 mM L-glutamine, and 60 mg/ml kanamycin sulfate. The
dissociated cells were plated at a density of 26105 cells/cm2 onto
six-well culture plates or four-chamber glass culture slides coated
with poly-D-lysine (Becton Dickinson Labware, Bedford, MA). To
obtain neuron-enriched cultures, the medium was replaced with
fresh medium supplemented with 2 mM cytosine-ß-D-arabinofur-
anoside (Ara-C) to inhibit the replication of non-neuronal cells, at
24 h after initial plating of dissociated cells, and then incubated for
Figure 4. Expression of DA and DAT in reactive astrocytes in the lesioned side of the striatum of hemi-parkinsonian rats after L-
DOPA administration. Confocal laser-scanning microscopic images of double immunofluorescein staining of DA (A; rhodamine; red) or DAT (B;
rhodamine; red) and GFAP (FITC; green) in the striatum of 6-OHDA-lesioned hemi-parkinsonian rats, and effects of repeated L-DOPA/carbidopa
treatment (50/5 mg/kg/day, i.p.) for 7 days. Lower panels show immunoreactivity to DA (A) and DAT (B). DA- and DAT-immunopositive signals (white
arrows) were observed in GFAP-labeled striatal astrocytes, especially on the lesioned side of PD models. Right small panels show higher magnification
images of immunopositive signals in the L-DOPA-treated PD models. Scale bar = 50 mm.
doi:10.1371/journal.pone.0106362.g004
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5 more days. In order to obtain glial-enriched cell cultures
(astrocytes), dissociated cells were incubated in the same culture
medium for 5–7 days, then subcultured and plated at a density
4.16104 cells/cm2, and finally incubated for another 7 days. Over
95% of these cultured glial-enriched cells showed GFAP immu-
noreactivity.
To measure monoamines and their metabolites in astrocytes,
the striatal astrocytes were plated onto 6-well plates (Becton
Dickinson) and grown in DMEM containing 10% FBS at a density
of 6.46104 cells/cm2 for 7 days. Then, astrocytes were treated
with 200 mM methyl-L-DOPA ester hydrochloride (methyl-L-
DOPA; Sigma-Aldrich, D1507) or 200 mM DA and were
incubated for 4 h or 8 h (Fig. 1, left). To examine the release of
L-DOPA from astrocytes after withdrawal of L-DOPA from the
culture media, the striatal astrocytes were treated with methyl-L-
DOPA (200 mM) for 8 h and then were incubated in fresh culture
medium for 1 h or 4 h after changing the medium (Fig. 1, middle).
For membrane-delimited coculture of striatal astrocytes with
mesencephalic neurons, subcultivated striatal astrocytes were
plated onto cell culture inserts for 6-well plates (0.4 mMmembrane
pore size; 4.2 cm2 of area; Becton Dickinson) at 1.26105 cells/cm2
on day 5, and were co-incubated with precultured mesencephalic
neurons on poly-D-lysin-coated 6-well plates for 2 days, and then
treated with methyl-L-DOPA (200 mM) for 4 h (Fig. 1, right).
The procedures used for each treatment are illustrated in Fig. 1.
After the final treatment or incubation, astrocytes were thoroughly
washed with PBS.
Fluorescence microscopy
All slides prepared for immunofluorescence studies of rat brain
sections and primary cultures were first observed under a
fluorescence microscope (Olympus BX50-FLA, Tokyo, Japan)
using a mercury lamp through a 470–490 nm or 530–550 nm
band-pass filter to excite Alexa Fluor 488/FITC or Alexa Fluor
594/rhodamine, respectively. Light emitted from Alexa Fluor
488/FITC or Alexa Fluor 594/rhodamine was collected through
515–550 nm band-pass filter or 590 nm long-pass filter, respec-
tively. Co-localization of GFAP-positive signals and L-DOPA-,
DA- or DAT-positive signals on immunostained brain sections was
confirmed by confocal laser-scanning microscopy (model LSM
510, Carl Zeiss, Jena, Germany). The 488 nm line of an argon-ion
laser attenuated to 5% of the maximal intensity with a neutral
density was used to excite Alexa Fluor 488/FITC. The 543 nm
line of a helium-neon laser without attenuation was used to excite
Alexa Fluor 594/rhodamine. Light emitted from Alexa Fluor 488/
FITC or Alexa Fluor 594/rhodamine was collected through a
505–530 nm band-pass filter or 560 nm long-pass filter, respec-
tively. Images were taken at 6400 magnification and recorded
using the Windows-based Zeiss LSM software. Adobe Photoshop
CS4 software (Adobe, Waltham, MA) was used for digital
amplification of the images.
RT-PCR
Neuron-enriched cells or glial-enriched cells (astrocytes) from
the striatum or mesencephalon on the six-well culture plates were
washed with 10 mM PBS, and the RNA was extracted by 800 ml
TRIzol reagent (Invitrogen, Carlsbad, CA). All samples were
treated with DNase I (Promega, Madison, MI). After completion
of cDNA synthesis with total RNA (1 mg), Oligo(dT)12-18 primer
(Gibco) and reverse transcriptase (Takara Bio Inc., Shiga, Japan),
10 ml of reverse transcriptase products were utilized for PCR in a
total volume of 50 ml using 1.25 U AmpliTaq Gold (Perkin-Elmer,
Branchburg, NJ) and specific primers for cDNA amplification of
rat DAT (GenBank accession number #M80233: upper 59-
CTTCACCAGAGCCGTGGCATTGATGAC-39 and lower 59-
TATTGTAACTGGAGAAGGCAATCAGC-39) [19]. PCR was
performed under the following conditions: denature at 95uC for
1 min, annealing at 58uC for 1 min, extension at 72uC for 2 min
in a total of 40 cycles, and a final extension at 72uC for 7 min. In
the next step, the PCR products (340 bp) were separated on a 2%
agarose gel and visualized by ethidium bromide staining.
Western blot analysis
Western blot analysis was performed as described previously
[20,21]. Briefly, cultured neuron-enriched cells or astrocytes from
the striatum or mesencephalon on six-well culture plates were
washed with 10 mM PBS, and then lysed in 150 ml of ice-cold
RIPA buffer [1 mM PBS, pH 7.4, 1% Nonident P-40, 0.5%
sodium deoxycholate, and 0.1% sodium dodecyl sulfate (SDS)]
plus a protease inhibitor (0.1 mg/ml phenylmethylsulfonyl fluoride
in isopropanol). After incubation on ice for 60 min, the
homogenates were centrifuged (19,2006g, 20 min at 4uC), and
then the supernatant of each sample was collected. The total
protein concentration of the cell lysates was determined by the
Lowry-based Bio-Rad DC protein assay kit (Bio-Rad, Richmond,
CA) with bovine serum albumin as a standard. Samples were
mixed with the sampling buffer (4% SDS, 0.02% bromophenol
blue, 20% glycerol, and 10% 2-mercaptoethanol in 125 mM Tris-
HCl, pH 6.8), and then boiled for 2 min. The proteins were
separated through a 12.5% SDS-polyacrylamide gel (Bio-Rad
Laboratories), and then electrophoretically transferred onto
nitrocellulose membranes (Hybond-ECL; Amersham Biosciences,
Buckinghamshire, UK).
The membranes were blocked in Tris-buffered saline with 0.1%
Tween-20 (TBS-T) containing 5% non-fat milk powder at room
temperature for 1 h. Then the blots were incubated with goat
polyclonal anti-DAT antibody (1:200, Santa Cruz Biotechnology,
Santa Cruz, CA, #K-20), rabbit polyclonal anti-L-type amino
acid transporter LAT1 antibody (dilution; 1:100, Serotec, Oxford,
UK, #AHP735), mouse monoclonal anti-4F2hc antibody (dilu-
tion; 1:200, BD Transduction Laboratories, #611516) or rabbit
polyclonal anti-aromatic L-amino acid decarboxylase (AADC)
antibody (dilution; 1:500, Protos Biotech Corporation, New York,
NY, #CA201 bDCrab) at room temperature for 1 h. After
washing with TBS-T (265 min), the blots were reacted with
donkey anti-goat IgG (Millipore), donkey anti-rabbit IgG (Amer-
sham Biosciences) or donkey anti-mouse IgG (Millipore) secondary
antibody conjugated with horseradish peroxidase (dilution; 1:2,000
or 5,000) at RT for 1 h. Specific signals of proteins were visualized
by chemiluminescence using the ECL Western blotting detection
system (Amersham Biosciences).
Figure 5. Changes in DA- and DAT-immunoreactivity on reactive astrocytes in the striatum of hemi-parkinsonian rats after L-DOPA
administration. The 6-OHDA-lesioned hemi-parkinsonian rats were treated with L-DOPA/carbidopa treatment (50/5 mg/kg/day, i.p.) for 7 days. The
densities of GFAP-positive reactive astrocytes (A), DA- and GFAP-double positive astrocytes (B) and DAT- and GFAP-double positive astrocytes (C) on
both the control and lesioned sides of the striatum were evaluated by double immunostaining of DA/DAT and GFAP at 3 h after the final
administration. Values are mean 6 SEM of 6–8 mice. *p,0.05, ***p,0.001 vs. side-matched vehicle-treated sham-operated, +++p,0.001 vs. side-
matched vehicle-treated parkinsonian group, #p,0.05, ##p,0.01, ###p,0.001 vs. intact control side of each treated group.
doi:10.1371/journal.pone.0106362.g005
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Measurement of intracellular L-DOPA, DA and its
metabolites
The striatal astrocytes treated with methyl-L-DOPA or DA
were homogenized with 5 volumes of 200 mM ice-cold perchloric
acid containing 10 mM EDTA. After centrifugation (11,7506g,
20 min at 4uC), the supernatant was filtered (0.45 mm) and then
injected directly into a high-performance liquid chromatography
with electrochemical detectors (HPLC-ECD, Tosoh Co., Tokyo)
to measure the concentrations of L-DOPA, methyl-L-DOPA, DA
and their metabolite DOPAC. The HPLC system consisted of a
delivery pump (PX-8020, Tosoh Co.) and an analytical column
(EICOMPAK SC-5ODS, 3.0 mm6150 mm, Eicom Co., Kyoto,
Japan). An electrochemical detector (EC-8020, Tosoh Co.) with
glassy carbon was used at a voltage setting of 700 mV and an Ag/
AgCl reference electrode. A mobile phase containing 0.1 M
citrate-sodium acetate buffer (pH 3.5), methanol (17% v/v),
EDTA-2Na, and sodium 1-octanesulfonate was infused at a flow
rate of 0.6 ml/min.
Statistical analysis
Results are presented as mean 6 SEM. Differences between
groups were analyzed by one-way or two-way ANOVA followed
by post-hoc Fisher’s PLSD test. A P value less than 0.05 denoted
the presence of a statistically significant difference.
Figure 6. Expression of DAT, LAT1, its subunit and AADC in primary cultured neurons and astrocytes from rat mesencephalon and
striatum. Detection of mRNA expression of DAT (A), protein expression of DAT (B), LAT1 (C), 4F2hc (D), and AADC (E) in primary cultured neurons (N)
and astrocytes (G) from mesencephalon (MC) and striatum (Str) of rat embryos using RT-PCR assay (A) and western blot analysis (B–E).
doi:10.1371/journal.pone.0106362.g006




L-DOPA ND 1349.7648.1 ND
DA ND ND 302.0641.9
DOPAC ND ND 3023.06579.7
8 h
control methyl-L-DOPA DA
L-DOPA ND 1213.36132.0# ND
DA ND ND 372.9623.5#
DOPAC ND ND 1204.96127.5#
Striatal astrocytes were treated with methyl-L-DOPA, DA (200 mM) or control vehicle for 4 h or 8 h. The concentrations of L-DOPA, DA and DOPAC were measured by
HPLC assay. ND: not detected. Data (pmol/mg protein) are presented as mean 6 SEM (n = 4).
#p,0.001 vs. the corresponding 4-h treated group.
doi:10.1371/journal.pone.0106362.t001
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Figure 7. Changes in extracellular and intracellular L-DOPA concentration in methyl-L-DOPA-pretreated primary cultured striatal
astrocytes after withdrawal of L-DOPA. Striatal astrocytes were treated with methyl-L-DOPA (200 mM) for 4 h or 8 h (filled bar). Furthermore,
astrocytes pre-treated with methyl-L-DOPA for 8 h were incubated in fresh medium for 1 h or 4 h (gray bar). The concentration of methyl-L-DOPA (A)
and L-DOPA (B) in culture media, and intracellular concentration of L-DOPA (C) in striatal astrocytes. Inset highlights the changes in L-DOPA
L-DOPA in Striatal Astrocytes
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Results
Expression of L-DOPA in the striatal astrocytes in hemi-
parkinsonian model rats
We performed double immunostaining of GFAP and L-DOPA
in the striatal sections of hemi-PD models that were repeatedly
injected with L-DOPA/carbidopa (50/5 mg/kg/day, i.p.) for 7
days, and co-localization of both signals were analyzed by confocal
laser-scanning microscopy. The 6-OHDA-lesioning markedly
increased GFAP-positive reactive astrocytes in the striatum (Figs. 2
and 3). Some GFAP-positive astrocytes showed L-DOPA-immu-
noreactivity in the lesioned side of vehicle-treated PD models.
Furthermore, the L-DOPA treatment apparently increased L-
DOPA-immunoreactivity in GFAP-positive striatal astrocytes on
the lesioned side in hemi-PD rats (Figs. 2 and 3).
Expression of DA and DAT in the striatal astrocytes in
hemi-parkinsonian models
Examination of the lesioned side of the striatum in 6-OHDA-
lesioned parkinsonian model rats showed apparent reduction of
diffuse DA- and DAT-immunopositive signals, together with
increased GFAP-immunopositive reactive astrocytes (Fig. 4). We
examined the expression of DA and DAT in striatal astrocytes in
hemi-parkinsonian rats that were repeatedly injected with L-
DOPA/carbidopa (50/5 mg/kg/day, i.p.) for 7 days by confocal
laser-scanning microscopy. Repeated L-DOPA injections induced
marked expression of DAT and apparent DA-immunoreactivity in
GFAP-positive reactive astrocytes on the lesioned side of the
striatum in hemi-PD rats (Figs. 4 and 5). To a lesser extent, some
GFAP-positive striatal astrocytes showed DA- and DAT-immu-
noreactivities in the lesioned side of vehicle-treated PD models.
Expression of DA, DAT, LAT and AADC in cultured
astrocytes
To confirm the expression of molecules related to DA or L-
DOPA uptake and metabolizing enzymes in astrocytes of basal
ganglia, we performed RT-PCR to detect DAT mRNA and also
western blot analysis for DAT, neutral amino acid transporter
LAT of L-DOPA transporter and AADC, which catalyzes L-
DOPA to DA, using primary cultured neuron-enriched cells or
astrocytes from the mesencephalon or striatum. Although striatal
neurons expressed neither DAT mRNA nor DAT protein,
astrocytes from the mesencephalon and striatum expressed both
DAT mRNA and protein, similar to mesencephalic neuron-
enriched cells (Fig. 6A, 6B). LAT1 and 4F2hc (light and heavy
chain of CD98 amino acid transporter, respectively) protein
expression was detected not only in neurons of the basal ganglia
but also in astrocytes of the mesencephalon and striatum (Fig. 6C,
6D). AADC protein expression was also detected in astrocytes of
mesencephalic and striatal astrocytes, although the expression
level in astrocytes was lower than in neurons (Fig. 6E).
Uptake and metabolism of L-DOPA and DA in striatal
astrocytes
We also measured the concentrations of L-DOPA, DA and their
metabolite in primary cultured striatal astrocytes after exposure to
methyl-L-DOPA or DA by HPLC, in order to clarify the uptake
and metabolism of L-DOPA and DA in striatal astrocytes (Fig. 1,
left, and Table 1). L-DOPA and DA were not detected in vehicle-
pretreated astrocytes. However, marked elevation of intracellular
DA and its metabolite DOPAC was noted in striatal astrocytes
treated with DA for 4 h and 8 h (Table 1). Treatment with
methyl-L-DOPA for 4 h induced marked increase in intracellular
L-DOPA level in striatal astrocytes (Table 1 and Fig. 7C). This
uptake of L-DOPA in striatal astrocytes was also noted at 8 h after
methyl-L-DOPA treatment (Table 1 and Fig. 7C). On the other
hand, methyl-L-DOPA in striatal astrocytes was undetectable
either 4-h or 8-h methyl-L-DOPA-treated group. The concentra-
tion of methyl-L-DOPA in astrocyte culture media was rapidly
decreased in a time-dependent manner after applying of methyl-L-
DOPA (200 mM) and it declined to undetectable level at 8-h
methyl-L-DOPA exposure (Fig. 7A), while the concentration of L-
DOPA in culture media reached to maximum level (,185 mM) at
4 h after the treatment (Fig. 7B). These indicate that applied
methyl-L-DOPA was rapidly converted to L-DOPA in culture
media, which was uptaken into astrocytes. Interestingly, however,
DA and DOPAC were not detected in striatal astrocytes of either
4-h or 8-h methyl-L-DOPA-treated group (Table 1), despite the
expression of AADC in striatal astrocytes (Fig. 6). When striatal
astrocytes were cocultured with mesencephalic neurons, intracel-
lular DA and DOPAC levels were increased in the astrocytes 4 h
after methyl-L-DOPA treatment (Table 2).
Finally, to examine the release of uptaken L-DOPA in
astrocytes, we measured changes in intracellular L-DOPA level
in methyl-L-DOPA-pretreated striatal astrocytes after withdrawal
of L-DOPA from the culture media (Fig. 1, middle, and Fig. 7).
The elevated intracellular level of L-DOPA in cultured striatal
astrocytes by pretreatment with methyl-L-DOPA for 8 h de-
concentration in fresh medium after removal of extracellular L-DOPA. Values are mean6 SEM (n= 4). *p,0.05, ***p,0.001 vs. control vehicle-treated,
###p,0.001 vs. 8-h methyl-L-DOPA-treated group.
doi:10.1371/journal.pone.0106362.g007







Striatal astrocytes cocultured with mesencephalic neurons using cell insert were treated with methyl-L-DOPA (200 mM) or control vehicle for 4 h. The concentrations of
L-DOPA, DA and DOPAC in striatal astrocytes were measured by HPLC assay. ND: not detected. Data (pmol/mg protein) are presented as mean 6 SEM (n = 4).
*p,0.001 vs. control group.
doi:10.1371/journal.pone.0106362.t002
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creased rapidly after removal of extracellular L-DOPA (Fig. 7C).
The level of L-DOPA in astrocytes reached the control level
following their incubation in fresh normal medium for 4 h. On the
other hand, the extracellular level of L-DOPA was increased at
1 h and 4 h after changing media (Fig. 7B).
Discussion
In the present study, we examined possible uptake of L-DOPA-
or DA- and the metabolic properties of striatal astrocytes using L-
DOPA-administered hemi-parkinsonian rats and L-DOPA/DA-
treated primary cultured striatal astrocytes. The main findings of
this study are: (1) striatal astrocytes can uptake L-DOPA and DA,
(2) the uptaken DA into striatal astrocytes is rapidly metabolized,
(3) the uptaken L-DOPA is not converted to DA despite AADC
expression in cultured striatal astrocytes, and (4) the intracellular
level of L-DOPA in striatal astrocytes decreased rapidly after
removal of extracellular L-DOPA.
It has been reported that certain receptors, channels and
transporters for neurotransmitters are also expressed in astrocytes
and are involved in neuron-astrocyte interaction [7,8,9,10]. We
reported previously that mRNAs and proteins of dopamine D1,
D4 and D5 receptors are expressed in primary cultured astrocytes
from the basal ganglia [22], suggesting that astrocytes as well as
post-synaptic neurons can respond to DA. Furthermore, the
reported expression of LAT and DAT in cortical and hippocampal
astrocytes [11,12,13,14,15] suggests that striatal astrocytes can
uptake L-DOPA and DA. In the present study, treatment with L-
DOPA/carbidopa for 1 week induced apparent L-DOPA- and
DA-immunoreactivities and marked DAT expression in reactive
astrocytes on the lesioned side of the striatum in hemi-parkinso-
nian rats. In mixed cultures of neurons and astrocytes, DA
treatment induced localized DA-immunoreactivity and increased
DAT expression in reactive striatal astrocytes. Furthermore,
primary cultured striatal astrocytes expressed DAT and LAT1
that can uptake DA and L-DOPA, respectively, and also expressed
AADC that converts L-DOPA to DA. To our knowledge, this is
the first report to show the expression of DAT and LAT in striatal
astrocytes. The results suggest that striatal astrocytes can uptake L-
DOPA and DA via LAT or DAT upon damage of dopaminergic
neurons, and that such L-DOPA2/DA-uptake property of
astrocytes may play an important role in L-DOPA metabolism
in the damaged dopaminergic neural system.
To further understand the process of L-DOPA and DA uptake
and metabolism in striatal astrocytes, the contents of L-DOPA,
DA, and their metabolites in primary cultured striatal astrocytes
were measured after L-DOPA/DA treatment. DA treatment
increased the levels of DA and its metabolite DOPAC in striatal
astrocytes, suggesting that released DA from the remaining DA
neurons in patients with PD can be uptaken into astrocytes and
rapidly metabolized. The level of L-DOPA in striatal astrocytes
was markedly increased, but DA was not detected after L-DOPA
exposure despite AADC expression in these cells. This finding
suggests that L-DOPA can be uptaken into astrocytes while the
uptaken L-DOPA is not converted to DA in astrocytes probably
due to inactive AADC in striatal astrocytes. The rapid metabolism
of the uptaken DA and minimal conversion of uptaken L-DOPA
to DA in striatal astrocytes may reduce the availability of L-DOPA
administered in damaged dopaminergic neurons. Therefore, the
strong DA signal in reactive astrocytes on the lesioned side of the
striatum in hemi-parkinsonian rats after long-term L-DOPA
administration may be due to DA synthesized from the uptaken
L-DOPA in surviving dopaminergic or serotonergic neurons. This
idea is supported by the present result that L-DOPA treatment
increased intracellular DA level in striatal astrocytes cocultured
with mesencephalic neurons but not in the case of astrocyte alone.
The low conversion of uptaken L-DOPA to DA in striatal
astrocytes raises the question of whether the uptaken L-DOPA in
astrocytes is retained or released. To answer this question, we
examined changes in intracellular L-DOPA level in L-DOPA-
pretreated striatal astrocytes after withdrawal of L-DOPA from the
culture media. Increased level of intracellular L-DOPA in cultured
striatal astrocytes decreased rapidly to the control level after the
removal of extracellular L-DOPA by changing media, and L-
DOPA was detected in the fresh media. Taken together, the
present results suggest that striatal astrocytes act as a reservoir for
L-DOPA to uptake or release L-DOPA depending on extracellular
L-DOPA concentration, but they cannot convert L-DOPA to DA.
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